Loop diuretic (subcutaneous delivery)

Class

Subcutaneous furosemide drug-device combination

Loop diuretics act on the Na-K-2Cl cotransporter (NKCC2) located in the thick ascending limb of the loop of Henle, a segment of the kidney's filtering tubule responsible for reabsorbing a large fraction of filtered sodium. Blocking this transporter prevents sodium, potassium, and chloride reabsorption, drawing water into the urine by osmosis and producing a potent diuresis. This mechanism is central to managing fluid overload in conditions such as heart failure, chronic kidney disease, and cirrhosis, where excess salt and water retention cause congestion, breathing difficulty, and swelling. Furosemide, the prototypical loop diuretic, is usually given orally or intravenously, but in advanced congestion the gut wall itself becomes swollen, impairing drug absorption and making oral dosing unreliable; intravenous dosing, in turn, generally requires a hospital or infusion setting. Delivering furosemide subcutaneously, through a small wearable pump, is intended to bypass unpredictable gut absorption while allowing administration outside the hospital. An extended-release oral formulation of a related loop diuretic, torsemide, addresses the same absorption and dosing-consistency problem through modified release kinetics rather than a device. Both approaches preserve the established biology of loop diuretics while changing how and where the drug reaches the body.